UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~March~~May 0906, 2026

CRYO-CELL INTERNATIONAL, INC.

(Exact name of Registrant as Specified in Its Charter)


Delaware	001-40767	22-3023093
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

700 Brooker Creek Blvd. Suite 1800
Oldsmar, Florida		34677
(Address of Principal Executive Offices)		(Zip Code)

     Registrant’s Telephone Number, Including Area Code: 813 749-2100

    

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.01 par value	CCEL	NYSE American LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On ~~March~~May 96, 2026, Cryo-Cell International, Inc. (~~“Cryo-Cell~~the "Company”) received a written notice ~~(the “Notice”)~~ from NYSE ~~American~~Regulation ~~LLC~~stating ~~(“NYSE~~that ~~American”)~~it ~~indicating~~had ~~that~~accepted the Company’s isplan ~~not~~to inregain compliance with the continued listing standards ~~set forth in Section 1003 (a)~~ of the NYSE American ~~Company~~LLC ~~Guide~~("NYSE American").

~~The~~As ~~Notice~~previously ~~has~~disclosed, nothe ~~immediate~~Company ~~effect~~submitted ona ~~the~~compliance ~~listing~~plan orto ~~trading~~NYSE ofAmerican ~~the~~on ~~Company’s~~April ~~common stock~~8, ~~which~~2026. ~~will~~NYSE ~~continue~~Regulation toaccepted ~~trade on~~ the ~~NYSE~~plan ~~American~~and ~~under~~granted the ~~symbol~~Company ~~“CCEL”~~a ~~while~~plan ~~the~~period ~~Company~~through ~~pursues~~September a9, ~~plan~~2027 to regain compliance with the applicable continued listing standards.

InDuring ~~accordance~~the ~~with~~plan ~~NYSE American procedures~~period, the Company’s ~~intends~~common tostock ~~submit~~will acontinue ~~plan~~to ofbe ~~compliance~~listed toand ~~NYSE~~traded ~~American~~on byNYSE ~~April 8~~American, ~~2026,~~subject ~~addressing how it intends~~ to ~~regain~~the Company’s compliance with the ~~continued~~initiatives ~~listing~~and ~~standards.~~conditions Ifset ~~the~~forth ~~plan~~in ~~is accepted, NYSE American may grant~~ the ~~Company~~compliance anplan ~~extension~~and ofcontinued ~~time~~periodic toreview ~~regain~~by ~~compliance~~NYSE Regulation.

~~The~~There ~~Company~~can isbe ~~currently~~no ~~evaluating~~assurance ~~its~~that ~~options~~the Company will be able to regain compliance with the NYSE American continued listing standards. ~~However~~by the September 9, ~~there~~2027 ~~can~~plan beperiod nodeadline. ~~assurance~~If ~~that~~the ~~NYSE~~Company ~~American~~fails ~~will~~to ~~accept~~regain ~~the~~compliance ~~Company’s~~by ~~plan~~such date, or ~~that~~fails ~~the~~to ~~Company~~make ~~will~~progress beconsistent ~~able~~with tothe ~~regain~~accepted compliance ~~within~~plan ~~any~~during ~~extension~~the plan period, ~~that~~NYSE American may beinitiate ~~granted~~delisting proceedings.

Item 7.01 – Regulation FD Disclosure

On ~~March~~May 128, 2026, the Company issued a press release announcing that itNYSE Regulation had ~~received~~accepted athe ~~notice~~Company’s ~~from~~plan to regain compliance with the NYSE American ~~LLC~~continued ~~indicating~~listing ~~that~~standards and granted the Company isa ~~not~~plan inperiod ~~compliance~~through ~~with~~September ~~certain~~9, ~~continued~~2027 ~~listing~~to ~~standards~~regain ~~of NYSE American~~compliance. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information furnished pursuant to this Item 7.01, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing.

The information furnished pursuant to this Item 7.01, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements And Exhibits.

(d) Exhibits

Exhibit No.	Description
99.1	Press Release dated ~~March~~May 128, 2026 announcing receipt of the notice
104	Cover page Interactive Data File (embedded in the cover page formatted in Inline XBRL)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

			Cryo-Cell International, Inc.
Date:	~~March~~May 128, 2026	By:	/s/ David Portnoy
			David Portnoy, Chairman and Co-CEO

Filing Compare · CRYO CELL INTERNATIONAL INC